Synovio Therapeutics

Company Overview

Snapshot

Founded in January 2025 by adi Sagiv Meister, Synovio Therapeutics operates with 1–10 employees. The company has secured funding across one round from one investor, with a significant grant received from the Israel Innovation Authority in September 2025.

Business overview

Synovio Therapeutics is a Health Tech & Life Sciences company focused on the development of novel drug candidates. The company's core technology involves Fenchone 1D, a specific agonist to the CB2 receptor, which is being developed as a treatment for Osteoarthritis. Operating within the Pharma & Medical Biotechnology sector, Synovio Therapeutics targets the Life Sciences and Pharmaceuticals markets with its drug discovery and development efforts.

Company Intelligence Q&A

What is Synovio Therapeutics' primary focus?

Synovio Therapeutics is focused on developing Fenchone 1D, a novel small molecule that acts as a specific agonist to the CB2 receptor, for the treatment of Osteoarthritis.

When was Synovio Therapeutics founded?

Synovio Therapeutics was founded in January 2025.

Who is the founder of Synovio Therapeutics?

adi Sagiv Meister is the founder of Synovio Therapeutics.

Which sector does Synovio Therapeutics operate in?

Synovio Therapeutics operates within the Health Tech & Life Sciences sector, with a specific focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Has Synovio Therapeutics received any funding?

In September 2025, Synovio Therapeutics received a grant from the Israel Innovation Authority.